PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme

Photo by Dmytro Vynohradov / Unsplash

medRxiv Published April 10, 2026 Medically reviewed April 25, 2026 Study authors: Garcia Rairan, L. A.; Corpus Gutierrez, v.; Del castillo, m. a.; Riveros Castillo, W.; Saavedra Gere… DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that PINK1 expression data in IDH-wild type GBM lacks reported survival outcomes in this prospective cohort.

This prospective observational cohort study investigated the prognostic value of PINK1 expression in patients with newly diagnosed IDH-wild type glioblastoma multiforme. The population consisted of adults aged 18 years and older who underwent surgical resection at four tertiary hospitals in Bogota, Colombia, including Hospital de Kennedy, Hospital El Tunal, Hospital Santa Clara, and Hospital Universitario de la Samaritana. The sample size included at least 26 to 50 participants. PINK1 expression was quantified using immunohistochemistry (IHC) as the primary exposure.

The primary outcomes assessed were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included functional status trajectories measured by Karnofsky Performance Status (KPS) or ECOG performance status. The follow-up period for the cohort was 24 months. Specific numerical results regarding survival rates or hazard ratios were not reported in the available data.

No adverse events, serious adverse events, discontinuations, or tolerability data were reported, as the study focused on prognostic biomarker quantification rather than therapeutic intervention. Consequently, safety information is not available from this source. The study design is observational, which limits the ability to infer causality between PINK1 expression levels and patient outcomes.

Key limitations include the lack of reported main results and the absence of a defined comparator group. Funding sources and potential conflicts of interest were not reported. Given the observational nature of the study and the incomplete reporting of primary outcomes, the practice relevance of these findings for clinical decision-making is currently unclear.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedApr 2026

View Original Abstract ↓

Introduction: Glioblastoma multiforme (GBM) remains the most lethal primary brain tumor with median survival of 14-15 months. Current prognostic markers inadequately stratify patient outcomes. PINK1 (PTEN-induced putative kinase 1), a mitochondrial kinase regulating mitophagy and cellular stress responses, has emerged as a promising prognostic candidate. Our preliminary analysis of 20 GBM cases demonstrated significant PINK1 expression with correlation to aggressive phenotypes (Turizo Smith et al., 2025). This multicenter study aims to prospectively validate PINK1 as a prognostic biomarker for survival and functional outcomes in a Latin American cohort. Methods and analysis: PINK1-GBM Colombia is a multicenter, observational cohort study across four tertiary hospitals in Bogota, Colombia (Hospital de Kennedy, Hospital El Tunal, Hospital Santa Clara and Hospital Universitario de la Samaritana). We will enroll at least 26-50 adults (18+ years) with newly diagnosed IDH-wild type GBM undergoing surgical resection. PINK1 expression will be quantified by immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) tissue using standardized protocols. Primary outcomes: overall survival (OS) and progression-free survival (PFS). Secondary outcomes: functional status trajectories (KPS/ECOG). Follow-up extends 24 months with clinical, imaging (RANO 2.0), and telephone assessments. Survival analyses will employ Kaplan-Meier methods, log-rank tests, and Cox proportional hazards models adjusted for established prognostic factors. Ethics and dissemination: Approved by Universidad Nacional de Colombia Ethics Committee (Acta 001, February 5, 2026; Ref: 2.FM.1.002-CE-002-26), Subred Sur Occidente (P-AP-19-2025, July 11, 2025), and Subred Centro Oriente (CEI 067/2025, October 24, 2025). Conducted per Declaration of Helsinki and Colombian Resolution 8430/1993. Results will be disseminated via peer-reviewed publication, international conferences, and thesis submission.

PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme

Study Details

Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer.

Digital mental health tools may help breast cancer patients feel better

Clinical research that matters. Delivered to your inbox.

PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme

More on Glioblastoma multiforme

Study Details

Digital and AI-supported psychosocial interventions modestly reduce distress and improve quality of life in women with breast cancer.

Digital mental health tools may help breast cancer patients feel better

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties